Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Minal Patel

Nurse Practitioner, Pediatrics Clovis, CA Nurse Practitioner

NPI 1851819742 CMS profile 10582341

726 N Medical Center Dr E Ste 205, Clovis, CA 93611

Open in the dashboard

General payments

$4,161

94 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Minal Patel of Clovis, CA is reported in the CMS Open Payments database as having received $4,161 across 94 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $917 32
2024 General $1,239 21
2023 General $818 19
2022 General $771 11
2021 General $416 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Minal Patel
  • Nurse Practitioner, Pediatrics median
  • Middle half of Nurse Practitioner, Pediatrics
  • National median

In program year 2025, general payments to Minal Patel were reported at $917. Among 7,458 Nurse Practitioner, Pediatrics profiles paid that year, the median was $93 and the middle half received between $35 and $201.

Show as a table
Year Minal Patel Nurse Practitioner, Pediatrics median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $416 $60 $23–$142 $132
2022 $771 $72 $27–$161 $149
2023 $818 $89 $35–$185 $160
2024 $1,239 $93 $34–$199 $164
2025 $917 $93 $35–$201 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Verrica Pharmaceuticals Inc. $694 22 payments
  2. ALK-Abello, Inc $374 7 payments
  3. Ultragenyx Pharmaceutical Inc. $323 3 payments
  4. Phadia US Inc. $313 8 payments
  5. Abbott Laboratories $267 3 payments
  6. Genzyme Corporation $266 2 payments
  7. Cranial Technologies, Inc $199 15 payments
  8. Kowa Pharmaceuticals America, Inc. $169 3 payments
  9. GlaxoSmithKline, LLC. $164 4 payments
  10. Seqirus USA Inc $158 3 payments
  11. Other $1,235 24 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,161 94 payments
Products named General payments · program years 2021–2025
  1. YCANTH $694 22 payments
  2. Crysvita $323 3 payments
  3. ImmunoCAP $313 8 payments
  4. TZIELD $277 3 payments
  5. Doc Band $199 15 payments
  6. ZORYVE $169 3 payments
  7. BEXSERO $164 4 payments
  8. FreeStyle Libre 2 $142 2 payments
  9. MONJUVI $125 1 payment
  10. VRAYLAR $125 1 payment
  11. Other $1,229 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

94 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Pediatrics in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record